Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amplia Therapeutics ( (AU:ATX) ) has shared an announcement.
Amplia Therapeutics Limited announced a change in the director’s interest notice for Dr. Robert Peach, reflecting a recent allotment of shares and options, as well as the expiry of certain options. This update is part of the company’s regulatory compliance and may impact the company’s stock dynamics and stakeholder interests.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company has a particular emphasis on fibrotic cancers, such as pancreatic cancer, and chronic diseases like idiopathic pulmonary fibrosis (IPF).
YTD Price Performance: 74.16%
Average Trading Volume: 7,216,964
Technical Sentiment Signal: Hold
Current Market Cap: A$79.53M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.